{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:43:22Z","timestamp":1773675802009,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Little is known about how the change from intravenous to subcutaneous vedolizumab in a real-life setting in inflammatory bowel disease patients on stable maintenance therapy affects clinical outcomes. We compared the data on vedolizumab serum trough concentration, efficacy, and safety prior to and six months after the switch from intravenous to subcutaneous vedolizumab. In total, 24 patients, 13 with ulcerative colitis (UC) and 11 with Crohn\u2019s disease (CD), were included. Mean serum trough concentration of intravenous vedolizumab was significantly lower than mean serum trough concentration of subcutaneous vedolizumab (p = 0.002). There was no significant difference between C-reactive protein levels, fecal calprotectin levels or clinical scores (Harvey\u2013Bradshaw index or Partial Mayo score) prior to transition to subcutaneous vedolizumab and after 6 months. In four (16.7%) patients, two CD and two UC, therapy was discontinued during the follow-up period with a median of 5 months (minimum\u2013maximum: 4\u20136). In all patients, therapy was discontinued due to loss of response. In total, 13 adverse events were reported by 11 patients, and the most common adverse event was COVID-19. No serious adverse events were reported. In conclusion, subcutaneous vedolizumab has shown to be effective and safe in patients on previously established maintenance therapy with intravenous vedolizumab.<\/jats:p>","DOI":"10.3390\/ph16020239","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T02:29:23Z","timestamp":1675650563000},"page":"239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience"],"prefix":"10.3390","volume":"16","author":[{"given":"Vlasta","family":"Or\u0161i\u0107 Fri\u010d","sequence":"first","affiliation":[{"name":"Faculty of Medicine, J. J. Strossmayer University of Osijek, 31000 Osijek, Croatia"},{"name":"Department of Clinical Laboratory Diagnostics, University Center Hospital Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Borzan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, J. J. Strossmayer University of Osijek, 31000 Osijek, Croatia"},{"name":"Department of Clinical Laboratory Diagnostics, University Center Hospital Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"\u0160ahinovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, J. J. Strossmayer University of Osijek, 31000 Osijek, Croatia"},{"name":"Department of Clinical Laboratory Diagnostics, University Center Hospital Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Borzan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, J. J. Strossmayer University of Osijek, 31000 Osijek, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Kurbel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, J. J. Strossmayer University of Osijek, 31000 Osijek, Croatia"},{"name":"Poliklinika Aviva, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn\u2019s Disease: Results From the VISIBLE 2 Randomised Trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Restellini, S., and Afif, W. (2021). Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061242"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.3748\/wjg.v27.i37.6231","article-title":"Therapeutic Drug Monitoring in Inflammatory Bowel Disease: The Dawn of Reactive Monitoring","volume":"27","author":"Albader","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1093\/ecco-jcc\/jjy222.614","article-title":"P490 A Vedolizumab Population Pharmacokinetic Model Including Intravenous and Subcutaneous Formulations for Patients with Ulcerative Colitis","volume":"13","author":"Rosario","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1093\/ecco-jcc\/jjy222.653","article-title":"P529 Exposure\u2013Response Relationship of Vedolizumab Subcutaneous Treatment in Patients with Ulcerative Colitis: VISIBLE 1","volume":"13","author":"Rosario","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.17153","article-title":"Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab Maintenance Treatment for Inflammatory Bowel Diseases","volume":"56","author":"Volkers","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"i378","DOI":"10.1093\/ecco-jcc\/jjab232.503","article-title":"P376 Switching from Intravenous to Subcutaneous Vedolizumab Maintenance Treatment; Feasibility, Safety and Clinical Outcome","volume":"16","author":"Wiken","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/ecco-jcc\/jjab224","article-title":"Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]","volume":"16","author":"Ventress","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/apt.16927","article-title":"Real-World Data on Switching from Intravenous to Subcutaneous Vedolizumab Treatment in Patients with Inflammatory Bowel Disease","volume":"55","author":"Bergqvist","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jonaitis, L., Markovi\u0107, S., Farkas, K., Gheorghe, L., Krznari\u0107, \u017d., Salupere, R., Mokricka, V., Spassova, Z., Gatev, D., and Grosu, I. (2021). Intravenous versus Subcutaneous Delivery of Biotherapeutics in IBD: An Expert\u2019s and Patient\u2019s Perspective. BMC Proc., 15.","DOI":"10.1186\/s12919-021-00230-7"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Remy, C., Caron, B., Gouynou, C., Haghnejad, V., Jeanbert, E., Netter, P., Danese, S., and Peyrin-Biroulet, L. (2022). Inflammatory Bowel Disease Patients\u2019 Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. J. Clin. Med., 11.","DOI":"10.3390\/jcm11247296"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Burdge, G., Hardman, A., Carbery, I., Broglio, G., Greer, D., and Selinger, C.P. (2022). Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195669"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Little, R.D., Ward, M.G., Wright, E., Jois, A.J., Boussioutas, A., Hold, G.L., Gibson, P.R., and Sparrow, M.P. (2022). Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease\u2014Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206173"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/apt.16937","article-title":"Real-world Multicentre Observational Study Including Population Pharmacokinetic Modelling to Evaluate the Exposure\u2013Response Relationship of Vedolizumab in Inflammatory Bowel Disease: ERELATE Study","volume":"56","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn\u2019s Disease","volume":"157","author":"Vermeire","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pouillon, L., Vermeire, S., and Bossuyt, P. (2019). Vedolizumab Trough Level Monitoring in Inflammatory Bowel Disease: A State-of-the-Art Overview. BMC Med., 17.","DOI":"10.1186\/s12916-019-1323-8"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/apt.16160","article-title":"Vedolizumab Treatment Persistence and Safety in a 2-Year Data Analysis of an Extended Access Programme","volume":"53","author":"Danese","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apt.15294","article-title":"Three-Year Effectiveness and Safety of Vedolizumab Therapy for Inflammatory Bowel Disease: A Prospective Multi-Centre Cohort Study","volume":"50","author":"Amiot","year":"2019","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A SIMPLE INDEX OF CROHN\u2019S-DISEASE ACTIVITY","volume":"315","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target Strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/2\/239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:24:46Z","timestamp":1760120686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/2\/239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,5]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ph16020239"],"URL":"https:\/\/doi.org\/10.3390\/ph16020239","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,5]]}}}